Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2015

01.08.2015 | Original Article

Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience

verfasst von: Trilokesh D. Kidambi, Amie Blanco, Megan Myers, Peggy Conrad, Kate Loranger, Jonathan P. Terdiman

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Lynch syndrome is the most common cause of hereditary colorectal cancer (CRC) and confers increased risk of other cancers. Identification of patients improves morbidity and mortality. Screening tumors for absent mismatch repair (MMR) protein expression by immunohistochemistry (IHC) is a recommended approach. Despite guidelines advocating universal screening, significant variation in clinical practice exists.

Aims/Methods

A retrospective study of two different IHC-based Lynch syndrome screening protocols at an urban, university hospital was performed. Outcomes from a “selective” screening strategy utilized from August 2007–July 2010 on CRC tumors from patients with high-risk features were compared with a “universal” strategy of screening all CRC tumors from July 2010–August 2013. Positively screened patients were referred for genetic counseling and offered germline testing.

Results

A total of 392 patients with CRC were screened: 107 selectively and 285 universally. The prevalence of Lynch syndrome was 3.1 %, with no difference by strategy. There was a trend (p = 0.06) toward fewer universally screened patients agreeing to genetic counseling compared with those selectively screened. Selective criteria failed to identify one of eight cases of Lynch syndrome from the universal group, though the universal strategy screened 166 additional tumors to find this additional patient.

Conclusions

Selective screening for Lynch syndrome has similar outcomes as universal screening in terms of identifying Lynch syndrome, despite screening far fewer patients. In addition, fewer eligible patients in our study agreed to undergo genetic counseling and germline testing than in prior studies. These lower rates may better reflect uptake of these services in clinical practice.
Literatur
1.
Zurück zum Zitat Umar A, Boland CR, Terdiman JP, et al. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268.PubMedCentralPubMedCrossRef Umar A, Boland CR, Terdiman JP, et al. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–268.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (hnpcc, lynch syndrome) proposed by the international collaborative group on hnpcc. Gastroenterology. 1999;116:1453–1456.PubMedCrossRef Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (hnpcc, lynch syndrome) proposed by the international collaborative group on hnpcc. Gastroenterology. 1999;116:1453–1456.PubMedCrossRef
3.
4.
Zurück zum Zitat Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in mlh1, msh2, and msh6 genes in lynch syndrome. JAMA. 2011;305:2304–2310.PubMedCrossRef Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in mlh1, msh2, and msh6 genes in lynch syndrome. JAMA. 2011;305:2304–2310.PubMedCrossRef
5.
Zurück zum Zitat Hampel H, Frankel WL, Martin E, et al. Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–1860.PubMedCrossRef Hampel H, Frankel WL, Martin E, et al. Screening for the lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–1860.PubMedCrossRef
6.
Zurück zum Zitat Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–1487.PubMedCrossRef Aaltonen LA, Salovaara R, Kristo P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med. 1998;338:1481–1487.PubMedCrossRef
7.
Zurück zum Zitat Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354:2751–2763.PubMedCrossRef Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354:2751–2763.PubMedCrossRef
8.
Zurück zum Zitat Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193–2200.PubMed Salovaara R, Loukola A, Kristo P, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18:2193–2200.PubMed
9.
Zurück zum Zitat Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for lynch syndrome: implications for personalized medicine. J Clin Oncol. 2013;31:2554–2562.PubMedCrossRef Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for lynch syndrome: implications for personalized medicine. J Clin Oncol. 2013;31:2554–2562.PubMedCrossRef
10.
Zurück zum Zitat Moreira L, Balaguer F, Lindor N, et al. Identification of lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–1565.PubMedCrossRef Moreira L, Balaguer F, Lindor N, et al. Identification of lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555–1565.PubMedCrossRef
11.
Zurück zum Zitat Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–834.PubMedCrossRef Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–834.PubMedCrossRef
12.
Zurück zum Zitat Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the lynch syndrome. N Engl J Med. 2006;354:261–269.PubMedCrossRef Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the lynch syndrome. N Engl J Med. 2006;354:261–269.PubMedCrossRef
13.
Zurück zum Zitat Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: a systematic review. JAMA. 2006;296:1507–1517.PubMedCrossRef Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to lynch syndrome: a systematic review. JAMA. 2006;296:1507–1517.PubMedCrossRef
14.
Zurück zum Zitat Gibson J, Lacy J, Matloff E, et al. Microsatellite instability testing in colorectal carcinoma: a practical guide. Clin Gastroenterol Hepatol. 2014;12:e171.CrossRef Gibson J, Lacy J, Matloff E, et al. Microsatellite instability testing in colorectal carcinoma: a practical guide. Clin Gastroenterol Hepatol. 2014;12:e171.CrossRef
15.
Zurück zum Zitat Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 1994;54:1645–1648.PubMed Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res. 1994;54:1645–1648.PubMed
16.
Zurück zum Zitat Terdiman JP, Gum JR Jr, Conrad PG, et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology. 2001;120:21–30.PubMedCrossRef Terdiman JP, Gum JR Jr, Conrad PG, et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germline genetic testing. Gastroenterology. 2001;120:21–30.PubMedCrossRef
17.
Zurück zum Zitat Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783–5788.PubMedCentralPubMedCrossRef Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783–5788.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Terdiman JP. It is time to get serious about diagnosing lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology. 2005;129:741–744.PubMedCrossRef Terdiman JP. It is time to get serious about diagnosing lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) in the general population. Gastroenterology. 2005;129:741–744.PubMedCrossRef
19.
Zurück zum Zitat Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12:93–104.PubMedCrossRef Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med. 2010;12:93–104.PubMedCrossRef
20.
Zurück zum Zitat Pinol V, Castells A, Andreu M, et al. Accuracy of revised bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986–1994.PubMedCrossRef Pinol V, Castells A, Andreu M, et al. Accuracy of revised bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293:1986–1994.PubMedCrossRef
21.
Zurück zum Zitat Schofield L, Watson N, Grieu F, et al. Population-based detection of lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer. 2009;124:1097–1102.PubMedCrossRef Schofield L, Watson N, Grieu F, et al. Population-based detection of lynch syndrome in young colorectal cancer patients using microsatellite instability as the initial test. Int J Cancer. 2009;124:1097–1102.PubMedCrossRef
22.
Zurück zum Zitat Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Int Med. 2011;155:69–79.PubMedCentralPubMedCrossRef Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Int Med. 2011;155:69–79.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Evaluation of Genomic Applications in P, Prevention Working G. Recommendations from the egapp working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from lynch syndrome in relatives. Genet Med. 2009;11:35–41.CrossRef Evaluation of Genomic Applications in P, Prevention Working G. Recommendations from the egapp working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from lynch syndrome in relatives. Genet Med. 2009;11:35–41.CrossRef
24.
Zurück zum Zitat Burt RW, Cannon JA, David DS, et al. Colorectal cancer screening. J Natl Compr Cancer Netw JNCCN.. 2013;11:1538–1575. Burt RW, Cannon JA, David DS, et al. Colorectal cancer screening. J Natl Compr Cancer Netw JNCCN.. 2013;11:1538–1575.
25.
Zurück zum Zitat Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for lynch syndrome among us cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30:1058–1063.PubMedCentralPubMedCrossRef Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for lynch syndrome among us cancer programs and follow-up of abnormal results. J Clin Oncol. 2012;30:1058–1063.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Cohen SA. Current lynch syndrome tumor screening practices: a survey of genetic counselors. J Genet Couns. 2014;23:38–47.PubMedCrossRef Cohen SA. Current lynch syndrome tumor screening practices: a survey of genetic counselors. J Genet Couns. 2014;23:38–47.PubMedCrossRef
27.
Zurück zum Zitat Bessa X, Balleste B, Andreu M, et al. A prospective, multicenter, population-based study of braf mutational analysis for lynch syndrome screening. Clin Gastroenterol Hepatol. 2008;6:206–214.PubMedCrossRef Bessa X, Balleste B, Andreu M, et al. A prospective, multicenter, population-based study of braf mutational analysis for lynch syndrome screening. Clin Gastroenterol Hepatol. 2008;6:206–214.PubMedCrossRef
28.
Zurück zum Zitat Heald B, Plesec T, Liu X, Pai R, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol. 2013;31:1336–1340.PubMedCrossRef Heald B, Plesec T, Liu X, Pai R, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol. 2013;31:1336–1340.PubMedCrossRef
29.
Zurück zum Zitat Gritz ER, Peterson SK, Vernon SW, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2005;23:1902–1910.PubMedCrossRef Gritz ER, Peterson SK, Vernon SW, et al. Psychological impact of genetic testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2005;23:1902–1910.PubMedCrossRef
30.
Zurück zum Zitat Sharaf RN, Myer P, Stave CD, et al. Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol. 2013;11:1093–1100.PubMedCrossRef Sharaf RN, Myer P, Stave CD, et al. Uptake of genetic testing by relatives of lynch syndrome probands: a systematic review. Clin Gastroenterol Hepatol. 2013;11:1093–1100.PubMedCrossRef
31.
Zurück zum Zitat Cross DS, Rahm AK, Kauffman TL, et al. Underutilization of lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med. 2013;15:933–940.PubMedCrossRef Cross DS, Rahm AK, Kauffman TL, et al. Underutilization of lynch syndrome screening in a multisite study of patients with colorectal cancer. Genet Med. 2013;15:933–940.PubMedCrossRef
32.
Zurück zum Zitat Chubak B, Heald B, Sharp RR. Informed consent to microsatellite instability and immunohistochemistry screening for lynch syndrome. Genet Med. 2011;13:356–360.PubMedCrossRef Chubak B, Heald B, Sharp RR. Informed consent to microsatellite instability and immunohistochemistry screening for lynch syndrome. Genet Med. 2011;13:356–360.PubMedCrossRef
33.
Zurück zum Zitat Williams JL, Williams MS. Informed consent and immunohistochemistry screening for lynch syndrome. Genet Med. 2011;13:848–849.PubMedCrossRef Williams JL, Williams MS. Informed consent and immunohistochemistry screening for lynch syndrome. Genet Med. 2011;13:848–849.PubMedCrossRef
34.
Zurück zum Zitat Ladabaum U, Ford JM. Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack. JAMA.. 2012;308:1581–1583.PubMedCrossRef Ladabaum U, Ford JM. Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack. JAMA.. 2012;308:1581–1583.PubMedCrossRef
Metadaten
Titel
Selective Versus Universal Screening for Lynch Syndrome: A Six-Year Clinical Experience
verfasst von
Trilokesh D. Kidambi
Amie Blanco
Megan Myers
Peggy Conrad
Kate Loranger
Jonathan P. Terdiman
Publikationsdatum
01.08.2015
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2015
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3234-z

Weitere Artikel der Ausgabe 8/2015

Digestive Diseases and Sciences 8/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.